Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
The anti-metabolite drug gemcitabine is widely used for the treatment of a variety of cancers. At present, gemcitabine is administered as a hydrochloride salt that is delivered by slow intravenous injection in cycles of three or four weeks. Although regarded as a ‘front-line’ chemotherapeutic agent,...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/11/3/597 |
id |
doaj-f45582da77124276bd16481be86b4c97 |
---|---|
record_format |
Article |
spelling |
doaj-f45582da77124276bd16481be86b4c972021-02-28T00:04:16ZengMDPI AGNanomaterials2079-49912021-02-011159759710.3390/nano11030597Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination TherapySaffiya Habib0Moganavelli Singh1Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaNano-Gene and Drug Delivery Group, Discipline of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaThe anti-metabolite drug gemcitabine is widely used for the treatment of a variety of cancers. At present, gemcitabine is administered as a hydrochloride salt that is delivered by slow intravenous injection in cycles of three or four weeks. Although regarded as a ‘front-line’ chemotherapeutic agent, its efficacy is hampered by poor target cell specificity, sub-optimal cellular uptake, rapid clearance from circulation, the development of chemoresistance, and undesirable side-effects. The use of organic, inorganic, and metal-based nanoparticles as delivery agents presents an opportunity to overcome these limitations and safely harness optimal drug efficacy and enhance their therapeutic indices. Among the many and varied nano delivery agents explored, the greatest body of knowledge has been generated in the field of lipid-mediated delivery. We review here the liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, exosomes, lipid-polymer hybrids, and other novel lipid-based agents that have been developed within the past six years for the delivery of gemcitabine and its co-drugs.https://www.mdpi.com/2079-4991/11/3/597lipidsnanosystemsgemcitabinedrug deliverycancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Saffiya Habib Moganavelli Singh |
spellingShingle |
Saffiya Habib Moganavelli Singh Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy Nanomaterials lipids nanosystems gemcitabine drug delivery cancer |
author_facet |
Saffiya Habib Moganavelli Singh |
author_sort |
Saffiya Habib |
title |
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy |
title_short |
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy |
title_full |
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy |
title_fullStr |
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy |
title_full_unstemmed |
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy |
title_sort |
recent advances in lipid-based nanosystems for gemcitabine and gemcitabine–combination therapy |
publisher |
MDPI AG |
series |
Nanomaterials |
issn |
2079-4991 |
publishDate |
2021-02-01 |
description |
The anti-metabolite drug gemcitabine is widely used for the treatment of a variety of cancers. At present, gemcitabine is administered as a hydrochloride salt that is delivered by slow intravenous injection in cycles of three or four weeks. Although regarded as a ‘front-line’ chemotherapeutic agent, its efficacy is hampered by poor target cell specificity, sub-optimal cellular uptake, rapid clearance from circulation, the development of chemoresistance, and undesirable side-effects. The use of organic, inorganic, and metal-based nanoparticles as delivery agents presents an opportunity to overcome these limitations and safely harness optimal drug efficacy and enhance their therapeutic indices. Among the many and varied nano delivery agents explored, the greatest body of knowledge has been generated in the field of lipid-mediated delivery. We review here the liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, exosomes, lipid-polymer hybrids, and other novel lipid-based agents that have been developed within the past six years for the delivery of gemcitabine and its co-drugs. |
topic |
lipids nanosystems gemcitabine drug delivery cancer |
url |
https://www.mdpi.com/2079-4991/11/3/597 |
work_keys_str_mv |
AT saffiyahabib recentadvancesinlipidbasednanosystemsforgemcitabineandgemcitabinecombinationtherapy AT moganavellisingh recentadvancesinlipidbasednanosystemsforgemcitabineandgemcitabinecombinationtherapy |
_version_ |
1724247750584827904 |